Leyden Labs
Manufacturing · Netherlands · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Emmy Noetherweg 2, Leiden, South Holland...Website
www.leydenlabs.comRevenue
$21.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Leyden Labs
Leyden Labs is developing nasal sprays that block airborne respiratory viruses at their point of entry. By delivering broadly protective antibodies directly to the respiratory mucosa, this approach provides immediate protection where infections begin. These antibody-based nasal sprays have the potential to protect everyone, even those with weakened immune systems.Explore more
Leyden Labs Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Leyden Labs your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Leyden Labs launches new products
Click to see if Leyden Labs had a recent Job posting/layoffs
Leyden Labs, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Leyden Labs
Funding: Get notified immidiatlly once Leyden Labs has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Leyden Labs recently announced quarterly report
Check if Leyden Labs has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Leyden Labs is spiking on competitors!
Recommended Actions
Find VP level buyers at Leyden Labs
Find 3 more new buyers
Company Profile Activity
Activity Insights
Leyden Labs is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Leyden Labs is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Leyden Labs.
Leyden Labs financials insights
Gather financial insights about Leyden Labs, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$45.2M
2022
Series B
$140M
2025
Other Financing Round
$70M
Other Financing Round
$35M
Leyden Labs Tech Stack
A closer look at the technologies used by Leyden Labs
Most Recent Scoops
Funding
Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Funding
Funding
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Leyden Labs News & Media
Leyden Labs Lands €20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities
LUXEMBOURG & LEIDEN, the Netherlands--(BUSINESS WIRE)--The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company’s broadly-protective antibodies to defend against seasonal and pandemic viral infections. Leyden Labs’ lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protectLeyden Labs Publishes New Data Confirming Potential of Intranasal Antibody Approach
LEIDEN, Netherlands--(BUSINESS WIRE)--Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced the publication of new findings that showcase the advantages of intranasal administration of monoclonal antibodies over systemic administration for protection against airborne viruses. The studies reported in this paper demonstrate the uniqueness of intranasal administration of broadly protective antibodies as a novel, non-vaccine approach to protect against respiratory viral infectioCoV Biotechnology Takes Next Step to Become Leyden Labs Asia
Advancing its Mission to Combat Respiratory Infectious Diseases SINGAPORE, SINGPORE, SINGAPORE, January 22, 2025 /EINPresswire.com/ -- - CoV Biotechnology has been acquired by Leyden Labs and continues as Leyden Labs Asia on the global biotech stage. …Leyden Labs Raises $70M to Advance its Intranasal Antibody Programs to Protect against Influenza and other Viruses
LEIDEN, the Netherlands--(BUSINESS WIRE)--Leyden Laboratories B.V. (the “Company” or “Leyden Labs”) today announced it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses. The funding round was supported by co-leads ClavystBio (a life sciences venture investor established by Temasek) and Polaris P
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Leyden Labs
Sign Up For FreeTo access detailed company insights
Leyden Labs is developing nasal sprays that block airborne respiratory viruses at their point of entry. By delivering broadly protective antibodies directly to the respiratory mucosa, this approach provides immediate protection where infections begin. These antibody-based nasal sprays have the potential to protect everyone, even those with weakened... Read More
